A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
Launched by BEIJING 302 HOSPITAL · Apr 11, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well different antiviral treatments work for children aged 1 to 12 years who have chronic hepatitis B (a long-lasting infection caused by the hepatitis B virus, or HBV). The study will enroll a total of 2,000 children, including those who have never been treated before (1,600 kids) and those who have been treated (400 kids). The goal is to see which treatments are most effective and safe for these young patients.
To participate, children must meet specific requirements. They should be between 1 and 12 years old, have tested positive for the hepatitis B virus for more than six months, and, for the treatment group, have been on antiviral medication for more than a year. Parents or guardians must provide consent for their child to join, and if the child is 8 years or older, they will need to sign as well. The trial is not yet recruiting participants, but it will provide valuable insights into managing chronic hepatitis B in children, helping doctors make better treatment decisions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Initial Treatment Group:
- • 1. The guardian understands and signs the informed consent form (both parents must sign), and adheres to the relevant requirements of this study. If the participant is 8 years old or older, they must also sign the informed consent form. For participants under 8 years old who can express consent, their consent must be clearly documented.
- • 2. Age: ≥1 year and \<13 years, either sex;
- • 3. Positive for HBsAg and/or HBV DNA for more than 6 months;
- • 4. No prior antiviral treatment.
- * Treated Group:
- • 1. The guardian understands and signs the informed consent form (both parents must sign), and adheres to the relevant requirements of this study. If the participant is 8 years old or older, they must also sign the informed consent form. For participants under 8 years old who can express consent, their consent must be clearly documented.
- • 2. Age: ≥3 years and \<13 years, either sex;
- • 3. Previously diagnosed with chronic hepatitis B and received antiviral treatment with NAs for more than 1 year and currently on treatment;
- • 4. No history of IFNα use in the past 6 months;
- • 5. Negative for HBV DNA;
- • 6. HBsAg quantification \<10,000 IU/ml (HBsAg can be negative in the drug discontinuation observation group);
- • 7. The drug discontinuation observation group must also achieve negative HBV DNA and HBeAg seroconversion for at least 1 year (based on continuous results from three consecutive reviews), and HBsAg \<10,000 IU/ml; NAs will be discontinued after enrollment.
- Exclusion Criteria:
- • 1.In the interferon group, blood white blood cell count \<3.5×10\^9/L, or platelet count \<80×10\^9/L, or prothrombin activity \<60%, or total bilirubin \>34μmol/L, or serum albumin \<35g/L, or serum creatinine \>133μmol/L; 2.Coexistence of other active infections; 3. Coexistence of other chronic liver diseases or active liver diseases, such as autoimmune liver disease, drug-induced liver injury, Wilson's disease, decompensated cirrhosis, liver cancer; 4. Coexistence of other severe systemic diseases or malignant tumors, etc.; 5. History of allergy to nucleoside analogues or interferon; 6. Subjects whom the investigator deems to have poor compliance, unable or unwilling to provide informed consent, or unable to adhere to the study requirements, or other conditions not suitable for participation in this study.
About Beijing 302 Hospital
Beijing 302 Hospital is a leading medical institution in China, renowned for its advanced clinical research and comprehensive healthcare services. As a sponsor of clinical trials, the hospital is committed to advancing medical knowledge and improving patient outcomes through rigorous scientific inquiry and innovation. With a multidisciplinary team of experienced researchers and healthcare professionals, Beijing 302 Hospital focuses on a wide range of therapeutic areas, employing state-of-the-art facilities and methodologies to ensure the highest standards of trial integrity and patient safety. The hospital's dedication to ethical practices and collaboration fosters an environment conducive to groundbreaking research and the development of new treatment modalities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hefei, , China
Nanchang, , China
Shenzhen, , China
Xiamen, , China
Nanning, , China
Dongguan, , China
Foshan, , China
Dalian, , China
Yongcheng, , China
Guangzhou, , China
Shanghai, , China
Xi'an, , China
Luoyang, , China
Nanyang, , China
Guangzhou, , China
Nanchang, , China
Xi'an, , China
Zhongshan, , China
Taiyuan, , China
Xinxiang, , China
Yuncheng, , China
Linfen, , China
Xuchang, , China
Zhumadian, , China
Ankang, , China
ürümqi, , China
Wuhan, , China
Xiamen, , China
Liuzhou, , China
Liaocheng, , China
Shijiazhuang, , China
Beijing, , China
Zhenzhou, , China
Xiamen, , China
Shangqiu, , China
Anyang, , China
Beihai, , China
Binzhou, , China
Changzhi, , China
Changzhou, , China
Chengdu, , China
Chengdu, , China
Dongying, , China
Foshan, , China
Guangzhou, , China
Haikou, , China
Handan, , China
Hepu, , China
Heze, , China
Jiangmen, , China
Lanzhou, , China
Lhasa, , China
Linfen, , China
Longyan, , China
Luzhou, , China
Nanchang, , China
Nanchang, , China
Nanning, , China
Putian, , China
Putian, , China
Qingdao, , China
Quanzhou, , China
Queshan, , China
Shangcheng, , China
Shangqiu, , China
Shangqiu, , China
Shaoguan, , China
Shihezi, , China
Shijiazhuang, , China
Suzhou, , China
Tai'an, , China
Taiyuan, , China
Weifang, , China
Weishi, , China
Xi'an, , China
Xichang, , China
Xining, , China
Xinxiang, , China
Xixian, , China
Xuchang, , China
Yantai, , China
Yulin, , China
Zibo, , China
ürümqi, , China
Patients applied
Trial Officials
Fusheng Wang
Study Director
Fifth Medical Center of Chinese PLA General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported